María Sereno

ORCID: 0000-0002-0207-2118
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Genetic factors in colorectal cancer
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal and Anal Carcinomas
  • Pharmacogenetics and Drug Metabolism
  • Cancer, Lipids, and Metabolism
  • Colorectal Cancer Surgical Treatments
  • Cancer Diagnosis and Treatment
  • RNA modifications and cancer
  • Gastric Cancer Management and Outcomes
  • Multiple Myeloma Research and Treatments
  • HER2/EGFR in Cancer Research
  • Metabolomics and Mass Spectrometry Studies
  • Cancer, Hypoxia, and Metabolism
  • Neutropenia and Cancer Infections
  • 14-3-3 protein interactions
  • Multiple and Secondary Primary Cancers
  • Lymphoma Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Sarcoma Diagnosis and Treatment

Madrid Institute for Advanced Studies
2021-2025

Universidad Autónoma de Madrid
2007-2025

Hospital Universitario Infanta Sofía
2016-2025

IMDEA Food
2021-2025

Universidad Europea
2022-2025

Consejo Superior de Investigaciones Científicas
2024

Hospital General Universitario de Ciudad Real
2015-2018

Sofia University
2015

GTx (United States)
2015

Sofia University "St. Kliment Ohridski"
2012-2015

Abstract Purpose: Paclitaxel, a widely used chemotherapeutic drug, can cause peripheral neuropathies leading to dose reductions and treatment suspensions decreasing the quality of life patients. It has been suggested that genetic variants altering paclitaxel pharmacokinetics increase neuropathy risk, but major causes interindividual differences in susceptibility toxicity remain unexplained. We carried out whole-exome sequencing (WES) study identify associated with neuropathy. Experimental...

10.1158/1078-0432.ccr-14-1758 article EN Clinical Cancer Research 2014-11-15

Radiation has a limited but relevant role in the adjuvant therapy of gastric cancer (GC) patients. Since Chk1 plays critical function cellular response to genotoxic agents, we aimed analyze GC as biomarker for radiotherapy resistance. We analyzed expression AGS and MKN45 human cell lines by RT-QPCR WB small cohort patient's samples. demonstrated that overexpression specifically increases resistance radiation cells. Accordingly, abrogation activity with UCN-01 its shChk1 increased sensitivity...

10.1038/srep21519 article EN cc-by Scientific Reports 2016-02-12

Lung cancer is one of the most common cancers, still characterized by high mortality rates. As lipid metabolism contributes to metabolic reprogramming, several genes are considered prognostic biomarkers cancer. Statins a class lipid-lowering compounds used in treatment cardiovascular disease that currently studied for their antitumor effects. However, exact mechanism action and specific conditions which they should be administered remains unclear. Here, we found simvastatin effectively...

10.1002/1878-0261.12816 article EN cc-by Molecular Oncology 2020-10-08

Abstract Background Peripheral neuropathy is the dose-limiting toxicity of many oncology drugs, including paclitaxel. There large interindividual variability in neuropathy, and several risk factors have been proposed; however, not replicated. Here we present a comprehensive study aimed at identifying treatment physiopathology-related paclitaxel-induced cohort well-characterized patients. Patients Methods Analyses included 503 patients with breast or ovarian cancer who received paclitaxel...

10.1634/theoncologist.2018-0418 article EN The Oncologist 2018-11-23

Survival data support the use of first-line osimertinib as standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront is superior to sequential first- or second-generation tyrosine kinase inhibitors (TKIs) followed by all patients. It impossible predict which patients are at high risk progression, and this constitutes a major limitation TKI approach.A total 830 plasma samples from 228 with stage IV,...

10.1016/j.ejca.2021.02.031 article EN cc-by-nc-nd European Journal of Cancer 2021-04-05

High-level MET amplification (METamp) is a primary driver in ∼1%–2% of non-small cell lung cancers (NSCLCs). Cohort B the phase 2 VISION trial evaluates tepotinib, an oral inhibitor, patients with advanced NSCLC high-level METamp who were enrolled by liquid biopsy. While study was halted before enrollment planned 60 patients, results 24 are presented here. The objective response rate (ORR) 41.7% (95% confidence interval [CI], 22.1–63.4), and median duration 14.3 months CI, 2.8–not...

10.1016/j.xcrm.2023.101280 article EN cc-by Cell Reports Medicine 2023-11-01

Nutrients, including bioactive natural compounds, have been demonstrated to affect key metabolic processes implicated in tumor growth and progression, both preclinical clinical trials. Although the application of precision nutrition as a complementary approach improve cancer treatments is still incipient practice, development powerful "omics" techniques has opened new possibilities for delivering nutritional advice patients. Precision may contribute improving plasticity function antitumor...

10.3389/fimmu.2025.1519978 article EN cc-by Frontiers in Immunology 2025-02-17

Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib a small molecule blocks activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 PDGFR approved advanced renal cell hepatocellular carcinoma (b, c). Many studies evaluated sorafenib in non-small-cell lung cancer (NSCLC), different...

10.1097/cad.0000000000000277 article EN Anti-Cancer Drugs 2015-08-01

Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy one of the most important dose-limiting toxicity this drug. It occurs in around 60-80% patients, and 15% them develop severe neuropathy. The pathophysiology oxaliplatin neurotoxicity remains unclear. SCN9A gene codifying for subtype sodium channel (type IX, subunit α) mutations are involved neuropathic perception. In study we investigated whether genetic variants were associated with risk patients...

10.1186/s12885-016-3031-5 article EN cc-by BMC Cancer 2017-01-19

Patients with lung cancer may suffer from sexual dysfunction (SD) related to oncological treatment. This is an under-recognized condition among clinicians. The aim of this study was describe the prevalence SD in a multicenter cohort patients. multicenter, cross-sectional, observational conducted between July 2023 and February 2024. Sexual function assessed by patient-reported outcome (PRO) system using sex-specific questionnaire. Descriptive analysis evaluation differences categorical...

10.1016/j.esmoop.2025.104539 article EN cc-by-nc-nd ESMO Open 2025-04-01

Abstract Purpose: Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half patients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to develop a model that could predict clinically meaningful response CRT by using formalin-fixed paraffin-embedded (FFPE) biopsies. Experimental Design: first carried out an exploratory screening candidate genes SAGE technology evaluate dynamic changes in RC transcriptome selected refractory...

10.1158/1078-0432.ccr-10-2257 article EN Clinical Cancer Research 2011-04-06

Lung cancer is currently one of the most common malignancies in world and peritoneal involvement rare these types tumors. Clinical manifestations metastases are also uncommon include intestinal perforation obstruction. The present study reviewed certain aspects complication illustrated it with four cases patients that were diagnosed primary lung carcinoma secondary carcinomatosis (PC). outcome poor they rarely respond to chemotherapy. Surgery successful majority cases.

10.3892/ol.2013.1468 article EN Oncology Letters 2013-07-15
Coming Soon ...